SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, open-label, parallel-group trialFang Zheng, Guozhong Gong, Yi Li et al.|International Journal of Infectious Diseases|2020Cited by 64
Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort studyMin Zhang, Guozhong Gong, Guangdi Li et al.|Hepatology International|2020Cited by 33
p53 controls hepatitis C virus non-structural protein 5A-mediated downregulation of GADD45α expression via the NF-κB and PI3K–Akt pathwaysDu Cheng, Guozhong Gong, Lei Zhao et al.|Journal of General Virology|2012Cited by 28
A Novel Protein Drug, Novaferon, as the Potential Antiviral Drug for COVID-19Fang Zheng, Guozhong Gong, Yanwen Zhou et al.|medRxiv|2020Cited by 14
Differences in IP-10, TLR4 and IRF5/3 between SVR and non-SVR HCV-1 patients treated with PEG-IFN and ribavirinMin Zhang, Guozhong Gong, Yongfang Jiang et al.|Molecular Medicine Reports|2017Cited by 4